Online Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 123 - Innovative Designs for Benefit of Patients
Type: Topic-Contributed
Date/Time: Monday, August 9, 2021 : 1:30 PM to 3:20 PM
Sponsor: Biopharmaceutical Section
Abstract #317475
Title: A Roadmap to Using Historical Controls in Clinical Trials, by Drug Information Association Innovative Design Scientific Working Group
Author(s): Mercedeh Ghadessi*
Companies: Bayer Pharamceuticals
Keywords: Hhistorial control; Rare diseases; Clinical trials; Simulation; Bayesian Statistics; Sensitivity Analysis
Abstract:

Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and inclusion of HCs, while maintaining scientific validity. This paper provides a comprehensive roadmap for planning, conducting, analyzing and reporting of studies using HCs, mainly when a randomized clinical trial is not possible. We review recent applications of HC in clinical trials, in which either predominantly a large treatment effect overcame concerns about bias, or the trial targeted a life-threatening disease with no treatment options. In contrast, we address how the evidentiary standard of a trial can be strengthened with optimized study designs and analysis strategies, emphasizing rare and pediatric indications. We highlight the importance of simulation and sensitivity analyses for estimating the range of uncertainties in the estimation of treatment effect when traditional randomization is not possible. Overall, the paper provides a roadmap for using HCs.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2021 program